During the 2019 novel coronavirus disease (COVID-19) outbreak, therapeutic strategies must be adapted for liver cancer patients balancing the benefit of surgical resection against the risk of contamination incurred by the patient. The impact of COVID-19 in liver cancer patients who undergo surgery is still unclear due to the scarcity of available data. Decisions to postpone scheduled surgery for high risk patients must be made.